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Abstract
Background: Idiopathic pulmonary fibrosis acute exacerbation (IPF-AE) constitutes IPF’s most devastating event,
representing the unexpected superimposition of diffuse alveolar damage of unknown etiology. Guidelines recommend
high-dose steroids treatment despite unproven benefit. We hypothesized that previous immunosuppression and the
administration of high-dose steroids adversely affect IPF-AE outcome.
Methods: We studied all consecutive patients hospitalized in our department for IPF deterioration from 2007 to
June 2013. Our protocol consisted of immediate cessation of immunosuppression (if any), best supportive care,
broad-spectrum antimicrobials and thorough evaluation to detect reversible causes of deterioration. Patients
were followed-up for survival; post-discharge none received immunosuppression.
Results: Twenty-four out of 85 admissions (28 %) fulfilled IPF-AE criteria. IPF-AE were analyzed both as unique
events and as unique patients. As unique events 50 % survived; 3 out of 12 (25 %) in the group previously
treated with immunosuppression whereas nine out of 12 (75 %) in the group not receiving immunosuppression
(p = 0.041). As unique patients 35.3 % survived; 3 out of 6 (50 %) in the never treated group whereas three out of
11 (27.3 %) in the group receiving immunosuppression (p = 0.685). The history of immunosuppression
significantly and adversely influenced survival (p = 0.035). Survival was greater in the never treated group
compared to the immunosuppressed patients (p = 0.022). Post-discharge, our IPF-AE survivors had an 83 % 1-year
survival.
Conclusions: By applying the above mentioned protocol half of our patients survived. The history of
immunosuppression before IPF-AE adversely influences survival. Avoiding steroids in IPF patients may favor the
natural history of the disease even at the moment of its most devastating event.
Keywords: Idiopathic pulmonary fibrosis acute exacerbation, Steroids, Immunosuppression, Survival
Background
Idiopathic pulmonary fibrosis (IPF) is a dreadful, chronic
and irreversibly progressive disease leading to death in all
patients affected and IPF acute exacerbations (IPF-AE)
constitute the most devastating event during its clinical
course [1, 2]. IPF-AE etiology is elusive although
infections, gastroesophageal reflux disease, lung surgery,
bronchoalveolar lavage, air pollution or alternatively a
hypothetic acceleration of IPF fibrotic process have been
suggested as triggering factors [2].
IPF-AE histological picture corresponds to the devel-
opment of diffuse alveolar damage (DAD) upon usual
interstitial pneumonia (UIP) [2]. This corresponds clinic-
ally to the development of an unknown etiology acute
respiratory distress syndrome (ARDS) in IPF. Although
IPF is an idiopathic condition with no proven therapy,
the common practice for the last decades was to treat
* Correspondence: papiris@otenet.gr
†Equal contributors
12nd Pulmonary Medicine Department, Attikon University Hospital, Athens
Medical School, National and Kapodistrian University of Athens, Athens,
Greece
Full list of author information is available at the end of the article
© 2015 Papiris et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Papiris et al. BMC Pulmonary Medicine  (2015) 15:162 
DOI 10.1186/s12890-015-0146-4
IPF with steroids and other immunosuppressants (espe-
cially azathioprine) a regimen that proved to be harmful
[3–5]. Similar, by steroids, still remains the approach to
treat IPF-AE as well [2–4] although there is no literature
proving the effectiveness of these drugs in IPF-AE.
Convinced of its harmfulness, years before the PAN-
THER trial [5], the triple therapy strategy was abandoned
in our everyday clinical practice and was appropriately
supported in previous publications together with our ad-
versity for the high-dose steroids regimen upon IPF-AE
[1, 6]. In the present study we aimed to test the hypothesis
that both a history of previous immunosuppression and
the administration of high-dose steroids adversely affect
IPF-AE outcome. Therefore our protocol consisted of im-
mediate cessation of immunosuppression (if any), best
supportive care, broad-spectrum antimicrobials and thor-
ough evaluation to detect reversible causes of deterior-
ation. All patients were followed-up for survival; after
discharge none received immunosuppression.
Methods
Firstly, we reviewed the files of all consecutive patients
admitted to the pulmonary department of a tertiary
teaching hospital, “Attikon” University Hospital, from
January 2007 to May 2011 with the diagnosis of pulmon-
ary fibrosis. Secondly, we isolated the cases that repre-
sented IPF according to the 2011 IPF criteria [3]. Among
these admissions we further separated the ones represent-
ing IPF-AE according to the IPF Clinical Research Net-
works Investigators consensus (IPF diagnosis, unexplained
worsening or development of dyspnea within 30 days, new
lung infiltrates (mainly ground glass upon honeycomb),
and exclusion of any identifiable or treatable cause of lung
injury) [2]. Finally, we prospectively recorded the patients
admitted with IPF and IPF-AE from June 2011 to June
2013 using the above mentioned criteria.
The protocol that we applied in every patient admitted
with the diagnosis of IPF deterioration has been de-
scribed in previous publications [1, 6] and consisted of
immediate cessation of immunosuppression (if any), best
supportive care (e.g. oxygen supplementation, pain-
killers, antifebrile medications, continuous monitoring of
the patient etc.), broad spectrum antimicrobials accord-
ing to the immune status of each patient, and thorough
evaluation to detect reversible causes of respiratory
deterioration. For all patients we recorded their demo-
graphics, smoking history, the last available pulmonary
function tests (PFTs) and 6 min walking distance before
hospitalization for AE, arterial blood gases, high-
resolution computed tomography (HRCT) of the chest
findings, lung biopsy, medications and comorbidities if
available. Each patient underwent both HRCT and CTPA
(computed tomography pulmonary angiography) to
safely exclude pulmonary embolism as an etiologic factor
of acute deterioration upon admission. Our patients
were also evaluated with blood tests (C-reactive protein,
procalcitonin, N-terminal-pro brain natriuretic peptide,
troponin, complete blood count, D-dimers, erythrocyte
sedimentation rate, serological studies for viruses,
Chlamydophila Pneumoniae, Mycoplasma Pneumoniae),
chest roentgenography, bronchoscopy, urinary antigen
tests for Streptococcus pneumoniae and Legionella
pneumophila, bronchoalveolar lavage (BAL), sputum
sampling, nasopharyngeal aspirates, endotracheal aspir-
ation, blood/sputum/BAL fluid cultures for microbes,
mycobacteria, atypical pathogens, opportunistic infec-
tions, fungi, viruses, PFTs and cardiac echocardiography,
whenever feasible taking into consideration the clinical
condition of each patient. We separated admissions di-
agnosed as IPF-AE in 2 groups. The first group consisted
of patients not receiving steroids or any other form of
immunosuppressants prior to admission (treatment
naïve or never treated) and the second group consisted
of patients receiving prior to admission steroids or any
other form of immunosuppressants (ever treated). Our
treatment consisted of extended spectrum antimicrobials
empirically initiated based mostly on the immunosup-
pression history of our patients. More precisely, patients
never treated with steroids or/and immunosuppressants
before the acute exacerbation event were set on antimi-
crobials for common gram positive, gram negative and
atypical pathogens plus therapy against influenza virus
pneumonia during the influenza season; patients previ-
ously treated with steroids or/and immunosuppressants
received in addition to the above mentioned therapy,
treatment for Pneumocystis jirovecii and occasionally for
cytomegalovirus pneumonia in a documented case. All
patients were followed-up after discharge for survival.
None of them was treated with steroids or immunosup-
pression post discharge.
This work has been approved by “Attikon” hospital’s
bioethics committee decision No 575/11-4-11. No pa-
tients’ consent was needed. Some of the data have been
published in the form of an abstract [7].
Statistical analysis
Categorical variables are presented as n (%). Numerical
variables are presented as median (range). Comparisons
between groups were performed using Cox regression
analysis in order to evaluate the influence of the previ-
ous use of immunosuppressive therapy on survival.
Results are presented as hazard ratios (HR) with 95 %
confidence intervals (CI) in parentheses. Time to death
according to previous history of immunosuppressive
therapy were evaluated with Kaplan-Meier survival
curves and log-rank tests. p values < 0.05 were consid-
ered statistically significant. Data were analyzed and
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graphs were created with StatsDirect 2.8.0, StatsDirect
Ltd, Altrincham, Chesire, UK.
Results
Out of 164 admissions with the diagnosis of pulmonary
fibrosis from January 2007 to May 2011, 53 were attrib-
uted to IPF representing 37 unique IPF patients. From
June 2011 to June 2013 another 32 cases with IPF were
admitted to our department (21 unique IPF patients). In
total from 2007 to 2013 we recorded 85 IPF admissions
that represent 58 unique IPF patients. Diagnosis was ob-
tained by multidisciplinary approach according to 2011
IPF guidelines [3] (Table 1). Out of these 85 IPF admis-
sions, 24 represent IPF-AE (17 unique IPF patients)
(Table 2). Fifteen IPF patients were admitted more than
once, two patients presented three episodes of IPF-AE
each one and one patient presented four episodes of
IPF-AE.
Among the 85 IPF admissions an identifiable cause of
the patient’s deterioration was found in 49 (58 %), that is
28 (33 %) cases of purulent tracheobronchitis, 7 (8 %)
cases of pneumonia, 6 (7 %) cases of heart failure, 4
(5 %) cases of sepsis, 2 (2 %) cases of pulmonary embol-
ism, 1 (1 %) case of pericarditis and 1 (1 %) case of
pneumothorax (Table 2). Twelve patients (14 %) were di-
agnosed as having progression of IPF. In total, respira-
tory causes of deterioration other than IPF-AE were
identified in 38 (45 %) of the cases. Adding the cases of
IPF-AE 24 (28 %) our results showed that the most com-
mon cause of deterioration in IPF was of respiratory
cause in three quarters of patients (73 %).
The descriptives of never and ever treated with steroid
groups are presented in Table 3. Each one of the never
and ever treated groups comprised 12 cases of IPF-AE.
Ever treated patients were previously treated with ste-
roids (10–25 mg prednisone/day) except for one patient
who was on methotrexate as well due to coexisting
psoriatic arthritis. The latter patient had no evidence of
any other autoimmune disease that could relate to the
UIP pattern observed. The present study extends chron-
ically before the official approval of pirfenidone; as a
result no study patient was on pirfenidone treatment.
Total lung capacity (TLC) in the never treated group
was significantly lower than in the ever treated (p = 0.007)
whilst the need for mechanical ventilation was signifi-
cantly increased in the ever treated group (p = 0.014). Re-
garding other parameters (sex, age, body mass index,
smoking history, emphysema, pulmonary hypertension,
other than TLC pulmonary function parameters, 6 min
walking distance, level of oxygenation, radiographic pat-
tern of IPF-AE, need for non-invasive ventilation during
hospitalization, time from IPF diagnosis to the exacerba-
tion event, previous long term oxygen therapy and BAL
performed) no significant difference was found (Table 3).
The majority of patients presented a normal cellular BAL
pattern; that is consisting mostly of alveolar macrophages
(>85 %), whereas only two patients had an abnormal BAL
differential-cell pattern consisting in one case of an in-
crease in lymphocytes and in one case in neutrophils.
As a total out of the 24 IPF-AE cases, 12 (50 %) sur-
vived the exacerbation event. In the never treated group
9 (75 %) patients survived whereas in the ever treated
group only 3 (25 %) patients did (p = 0.041). When
examining the IPF-AE not as unique events but as
unique patients (that is excluding from the analysis the
subsequent IPF-AE that developed in some patients after
the first exacerbation), then out of 17 IPF-AE patients, 6
(35.3 %) survived the exacerbation event. In the never
treated group which comprised 6 patients, 3 (50 %)
survived whereas in the ever treated group which
comprised 11 patients only 3 (27.3 %) patients did
(p = 0.685). A univariate Cox regression analysis identi-
fied the previous use of steroids as significantly and ad-
versely influencing survival after AE in the ever and never
treated groups, with a HR of 3.544 (95 % CI 1.090–
11.514), p = 0.035 (Table 4). The same analysis in the first
only exacerbation episode of the 17 unique IPF patients
failed to reach statistical significance HR 1.642 (95 % CI




Pattern (n = 15)
Diagnosis of
IPF (n = 58)
UIP UIP 7
UIP Probable UIP 2
UIP Possible UIP 0
UIP no biopsy 43
Possible UIP UIP 4
Possible UIP Probable UIP 2
HRCT High Resolution Computed Tomography; UIP Usual
interstitial pneumonia
Table 2 Causes of deterioration in IPF patients, n = 85 (100 %)
IPF exacerbation
n = 24, (28 %)
IPF progression
n = 12, (14 %)
Respiratory causes
n = 38, (45 %)
Non-
respiratory
causes n = 11,
(13 %)
Respiratory infection,
n = 35 (40 %)
Heart failure,
n = 6 (7 %)
Tracheobronchitis,
n = 28 (33 %)
Sepsis,
n = 4 (5 %)
Pneumonia,
n = 7 (8 %)
Pericarditis,
n = 1 (1 %)
Pulmonary embolism,
n = 2 (2 %)
Pneumothorax,
n = 1 (1 %)
IPF idiopathic pulmonary fibrosis
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0.441–6.119), p = 0.46 and the same applies to all others
variables studied (Table 4).
Overall our IPF-AE population had a median survival
of 1.73 months (range 0.1–89) with a 52 % 1-month,
45 % 3-month, 40 % 6-month and 40 % 1-year survival
respectively. In the never treated group there was a 70 %
1-month, 65 % 3-month, 65 % 6-month and 65 % 1-year
survival respectively (median survival could not be cal-
culated for the never treated group since more than half
of our patients were still alive at the day of census),
whereas in the ever treated group the median survival
was 0.43 months (range 0.2–89) with a 30 % 1-month,
22 % 3-month, 17 % 6-month and 17 % 1-year survival
respectively. These differences in survival following a
log-rank test were found to be statistically significant
(p = 0.022) (Fig. 1). After discharge 83 % of survivors (i.e.
patients that were discharged from the hospital after IPF-
AE) of both groups were still alive on the day of census
(28th February 2014). The survivors of IPF-AE treated with
our protocol present a 100 % 1-month, 90 % 3-month,
83 % 6-month and 83 % 1-year survival respectively (Fig. 2).
Discussion
This study has shown that treating rapidly deteriorating
IPF patients who develop the so called IPF acute exacer-
bation, avoiding steroids and providing them broad
spectrum antimicrobials, best supportive care and thor-
ough evaluation to detect reversible causes of deterior-
ation, positively influences survival since 50 % of our
patients survived. Furthermore, this study has shown
that patients previously treated with steroids and/or
immunosuppressants presented a less favorable response
to the above mentioned protocol since they showed a
poorer survival in comparison to those never treated
when examined either as unique events or as unique pa-
tients, although the statistical significance was reached
only in the first analysis. In the case of unique patients
the smaller number of patients is probably responsible
for not reaching the level of statistical significance. Our
findings refer to a population of ever and never treated
IPF-AE patients that present similar characteristics in
terms of the exacerbation’s severity. The only statistical
significant differences (lower TLC in the never treated
Table 3 Descriptives of IPF-AE patients never and ever treated with steroids and immunosuppressants before hospital admission
Descriptives IPF-AE Never treated Ever treated
Sex 15 male / 9 female 6 male / 6 female 9 male / 3 female p = 0.400
Age (years) 69.5 (52–82) 71.5 (52–80) 68 (52–82) p = 0.270
Smoking (p-y) 40 (0–110) 35 (0–60) 42.5 (0–110) p = 0.515
BMI 25.35 (17.6–32) 24.93 (22.49–31.2) 27.4 (17.6–32) p = 0.081
Emphysema 4 yes, 20 no 1 yes, 11 no 3 yes, 9 no p = 0.590
PH 4 yes, 6 no, 6 NA 3 yes, 6 no, 2 NA 3 yes, 4 no, 4 NA p = 1
FVC (lt) 2.01 (0.59–3.17) 1.9 (0.59–2.43) 2.52 (1.34–3.17) p = 0.056
FVC % predicted 63 (27.1–94) 53.15 (27.1–81.8) 65.1 (34.3–94) p = 0.646
FEV1 (lt) 1.57 (0.56–2.78) 1.43 (0.56–1.88) 1.86 (1.25–2.78) p = 0.055
FEV1 % predicted 60.6 (31.3–79) 53.5 (31.3–70.2) 70.2 (41.7–79) p = 0.074
TLC (lt) 3.21 (2.44–4.64) 2.84 (2.44–4.23) 4.04 (2.84–4.64) p = 0.007
TLC % predicted 57.2 (38.7–86.9) 52.2 (38.7–86.9) 57.5 (55.9–75) p = 0.101
DLCO (ml/min/mmHg) 2.68 (1.69–4.49) 2.68 (1.69–4.49) 3.13 (1.9–3.85) p = 0.619
DLCO % predicted 38.3 (19.6–54.3) 37.4 (19.6–54.3) 38.3 (24–38.9) p = 0.865
6MWD (meters) 272 (150–492) 271.5 (153–492) 272 (150–441) p = 0.932
Disease duration 43 (0–96) 49 (0–77) 34 (6–96) p = 0.744
Pattern of GGO in HRCT 5 peripheral, 8
multifocal, 8 diffuse, 3 NA
3 peripheral, 5 multifocal,
3 diffuse, 1 NA
2 peripheral, 3 multifocal,
5 diffuse, 2 NA
p = 0.444
NIMV 2 0 2 p = 0.478
Mechanical ventilation 6 0 6 p = 0.014
LTOT 6 3 3 p = 0.640
PO2/fiO2 163.5 (66–314.29) 181.25 (116.6–266.6) 152.95 (66–314.29) p = 0.378
BAL performed 6 yes, 18 no 3 yes, 9 no 3 yes, 9 no p = 0.640
Data are presented as median values
IPF-AE idiopathic pulmonary fibrosis acute exacerbation; BMI body mass index; PH pulmonary hypertension; FVC (forced vital capacity); FEV1 forced expiratory
volume in first second; TLC total lung capacity; DLCO diffusing capacity of the lung in carbon monoxide; 6MWD six minute walking distance; NA not available; GGO
ground-glass opacities; HRCT high resolution computerized tomography; NIMV non-invasive mechanical ventilation; LTOT long-term oxygen therapy; PO2 arterial
pressure of oxygen; fiO2 fraction of inspired oxygen; BAL bronchoalveolar lavage
Papiris et al. BMC Pulmonary Medicine  (2015) 15:162 Page 4 of 9
group and need for mechanical ventilation in the ever
treated group) further validate our hypothesis that on
the one hand provided a survival benefit in patients with
lower lung capacity and on the other hand patients with
higher lung capacity and comparable parameters of the
exacerbation severity could not be helped by the applied
protocol, thus were intubated and subsequently expired.
In addition, median overall survival of those ever treated
was just 0.43 months with a 17 % 1-year survival while
never treated patients showed a 1-year survival of 65 %.
Table 4 Univariate Cox regression analysis influencing outcome in the ever and never treated IPF-AE groups
Variable HR 95 % CI p-value
Age 0.968 0.919–1.020 0.221
Gender 1.927 0.600–6.186 0.270
Smoking (pack-years) 1.000 0.980–1.020 0.996
FEV1 (% predicted) 1.000 0.941–1.063 0.990
FVC (% predicted) 1.001 0.961–1.043 0.943
TLC (% predicted) 1.034 0.976–1.096 0.252
DLCO (% predicted) 1.044 0.963–1.319 0.293
Charlson comorbidity index 0.729 0.466–1.143 0.169
LTOT 1.138 0.356–3.631 0.829
Pattern of GGO in HRCT 1.650 0.737–3.696 0.223
PO2/fiO2 0.990 0.980–1.001 0.067
NIMV 2.014 0.449–9.039 0.361
Mechanical ventilation 1.966 0.646–5.992 0.234
Disease duration 1.014 0.995–1.034 0.156
Previous corticosteroid use (all exacerbation events) 3.544 1.090–11.514 0.035
Previous corticosteroid use (unique patients) 1.642 0.441–6.119 0.460
BAL performed 0.676 0.188–2.427 0.548
6MWD 0.999 0.994–1.005 0.918
IPF-AE idiopathic pulmonary fibrosis acute exacerbation; FVC forced vital capacity; FEV1 forced expiratory volume in first second; TLC total lung capacity; DLCO
diffusing capacity of the lung in carbon monoxide; LTOT long-term oxygen therapy; GGO ground glass opacities; HRCT high-resolution computerized tomography;
PO2 arterial pressure of oxygen; fiO2 fraction of inspired oxygen; NIMV non-invasive mechanical ventilation; BAL bronchoalveolar lavage; 6MWD six minute walking
distance; HR hazard ratio; CI confidence of interval
Fig. 1 Kaplan-Meier survival curves of patients with IPF acute exacerbation ever treated (black line), never treated (red line) with steroids and
immunosuppressants and of the overall population (green line) (p = 0.022)
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Finally, withholding steroids in all survivors of our
protocol 83 % of them were still alive 1 year after the ex-
acerbation event.
In 2012 a randomized, double-blind, placebo-controlled
trial based on an independent protocol reviewed by a
committee appointed by the National Heart, Lung, and
Blood Institute, and conducted in 25 clinical centers under
the auspices of the Idiopathic Pulmonary Fibrosis Clinical
Research Network (IPFnet) was terminated prematurely
when the interim analysis demonstrated that IPF patients
treated with combination therapy with prednisone, azathi-
oprine and N-acetylcysteine not only had no evidence of
physiological or clinical benefit but presented significantly
increased rate of hospitalizations, exacerbations and
deaths compared to the placebo arm [5]. Six percent of
treated patients in particular developed an acute exacerba-
tion compared with none in the placebo group. The find-
ings of our study concerning the difference in mortality
between the never and ever treated patients could further
extend the results of the PANTHER trial by providing
evidence that immunosuppression does not only increase
the number of acute exacerbation events but also ad-
versely affects outcome.
Based on the above evidence it appears to us
inconceivable to continue managing IPF patients who
precipitate in acute exacerbation being under immuno-
suppressive treatment with a thirty to hundred fold
higher doses of steroids (from 10–35 mg prednisone for
the stable IPF patient to 1000 mg methylprednisolone
iv pulses for one or more days) and await improvement.
The results of our study present our management ap-
proach of the rapid deteriorating patient with IPF
entering exacerbation by withdrawing corticosteroids
and immunosuppressants.
Our treatment, as already described, consisted of
extended spectrum antimicrobials empirically initiated
based mostly on the immunosuppression history of our
patients. The protocol adopted by us reflects the
common practice in every critical care unit where the
critically ill patient developing an ARDS of unknown eti-
ology, or during the evaluation for the detection of the
etiologic factor, is managed not by high doses of pulse
steroids but by extended spectrum antimicrobials since
in this setting it is known that undetectable infection is
the most common and the most treatable etiologic con-
dition. Certainly by adopting the above protocol we are
conscious that the results of our study are not easily
comparable with previous retrospective studies describ-
ing the efficacy of specific pharmacological treatment
with steroids and immunosuppressants in IPF-AE be-
cause such an alternative approach has not been exam-
ined before.
Current practice for steroids use in IPF acute exacerba-
tions originates from the first description of IPF-AE by
Kondoh and coworkers in 1993 [8] who also expressed
the fundamental dilemma whether the observed DAD de-
veloping upon UIP was any etiology ARDS upon IPF or
an accelerated phase of IPF itself. Kondoh and coworkers
adopted the second hypothesis and treated their patients
with high-dose steroids based on the common belief in
those times that steroids are able to modify IPF course.
Non-specifying any additional treatment and the eventual
use of antimicrobials Kondoh and coworkers reported
100 % success rate for IPF AE. Both Kondoh’s hypothesis
Fig. 2 Kaplan-Meier survival curves of patients with IPF acute exacerbation treated with the study protocol after hospital discharge (black line)
that showed an 83 % 1-year survival. Patients that died while hospitalized are shown in red line and the overall IPF acute exacerbation population
in green line
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that DAD upon UIP represents an accelerated phase of
IPF and Kondoh’s treatment approach with high dose ste-
roids pulses were adopted by the international community
and remain a recommendation on the current guidelines
despite the fact that similar results were never reproduced
by other investigators handling similar patients [3] and
despite the results of the PANTHER trial [5].
In our study the never treated IPF-AE population pre-
sented a 65 % 1-year survival compared to a 1-year
survival of 17 % and a median survival of only
0.43 months in the ever treated group. The overall
differences in survival as discussed in the results are
significant (p = 0.022). In contrast, the reported mortal-
ity of IPF-AE in most studies is very high, usually exceed-
ing 50–60 % and the 3-month mortality rate following an
exacerbation event reaches 60–90 % [2, 9–11]. Song and
coworkers in the largest report yet published, described 90
cases of IPF-AE with a 2.2 months median survival, a
50 % in-hospital mortality and a 60 % 3-month and 73.1 %
1-year mortality [12]. In 2003 Inase and coworkers de-
scribed 13 IPF-AE patients treated with methylpredniso-
lone and 7 among them with cyclosporin A as well, that
had a 1-month and 3-month mortality of 15 % and 46 %
respectively; 3 patients were also treated with trimetho-
prim/sulfamethoxazole [13]. The same treatment (methyl-
prednisolone, cyclosporin A, trimethoprim/sulfamethoxazole)
was used by Sakamoto and coworkers to treat 11 IPF-
AE patients with a mean survival of 135 days [14].
Because of the interpretation of data and the use of
mean instead of median values it is quite difficult to
render these results comparable to the results of other
studies. However, Okamoto, in the largest study to de-
scribe the effectiveness of methylprednisolone plus
cyclophosphamide or cyclosporine A in 28 patients
with IPF-AE had a 1-month mortality of 85.7 % [15].
Kondoh and coworkers described 3 UIP patients
(among 236 patients undergoing surgical lung biopsy
for diffuse lung disease) that developed an IPF-AE and
were treated with methylprednisolone pulses, immuno-
suppressants (2 patients) and antibiotics and presented
a 33 % 3-month and 66 % 6-month mortality respect-
ively [16]. Yokoyama described the impact of noninva-
sive ventilation in IPF-AE and the 11 patients
presented were also treated with steroids, antibiotics
and some of them with immunosuppressants as well
[17]. Median survival was 30 days, and 3-month and 6-
month mortality 54.5 % and 70 % respectively. Mora-
wiec and coworkers in 2011 described 11 patients with
IPF-AE and 7 with subacute exacerbation treated with ste-
roids and cyclophosphamide that had a 100 % 1-month
survival, a 72 % (55 % in the cases of IPF-AE) 3-month,
56 % 6-month and 33 % 1-year survival respectively; 6 pa-
tients received antibiotics for a suspected undocumented
respiratory infection with positive outcome [18]. Finally,
Simon-Blancal and coworkers treated 37 IPF-AE patients
with methylprednisolone pulses and methotrexate and
described a 27 % in-hospital mortality with a 4.2 months
median survival, the highest ever described; 32 patients re-
ceived broad spectrum antibiotics as well [19]. In many of
these studies apart from methodological issues and the
small number of patients it is imperative to notice that
many or all of the patients received broad spectrum anti-
biotics. In some studies the use (or not) of antibiotics is
not mentioned at all. However, to our opinion it is difficult
to understand why in the majority of cases the authors do
not consider the use of antibiotics as a treatment for IPF-
AE and they do not consider it to be a determinant of out-
come even when they use antibiotics, although experts
opinion recommend the use of antibiotics in all cases of
IPF-AE [20] and this reflects common practice worldwide.
In our opinion the use of antibiotics is of cardinal import-
ance to judge IPF-AE studies results and to treat IPF-AE
and this is the main reason why it was included as the
major therapeutic strategy in our treating protocol [6, 21].
The survival benefit in IPF-AE patients treated with
broad spectrum antimicrobials instead of high dose ste-
roids shown in the present study could be attributed to
the fact that they militate the role that microbial popula-
tions play in the pathogenesis of such a condition. It is
common knowledge that IPF is a disease that severely
damages the lung and that IPF lung is vulnerable to any
hit, even minor, that could cause DAD in the same man-
ner that direct and indirect lung injuries cause ARDS
[22]. Combining this vulnerable substrate with steroids
or immunosuppressants would substantially increase
the chances of microbes to induce an IPF deterioration
[1, 23, 24] especially since recently it is shown that hu-
man lung microbiome and any changes in its number
and composition play an important role in the patho-
genesis and progression of lung diseases, IPF included
[25, 26]. In the present study 40 % of our IPF patients
presented deterioration due to an infectious etiology. In
the literature it is shown that patients with interstitial
pneumonia receiving oral steroids have 16.3 times more
chances to be colonized by Pneumocystis jirovecii than
patients not receiving steroids and 36 % of IPF patients
grow bacteria in BAL fluid in the absence of clear signs
of infection, even before immunosuppression [23, 27].
More recently Molyneaux and co-workers described an
increased bacterial burden in BAL of IPF patients that
even predicts the decline in lung function and the death
of these patients [28]. Moreover a thorough review of
real life patients diagnosed and treated as IPF-AE, re-
veals many infective and non-infective complications of
steroids [29]. Wootton and coworkers applying array-
based detection found evidence of viral infection in
35 % of IPF-AE [30]. All the above findings reinforce
our hypothesis that IPF-AE is an ARDS considered so
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far of “unknown etiology” that could however be easily
triggered by the most “usual suspect” named infection,
a process that should be fought with priority.
It is to be noted that a limitation of the present study
is the small number of patients. Furthermore, it does not
include a control arm of IPF-AE patients treated with
high dose steroids. The main reason for such a “limita-
tion” was firstly our long standing clinical experience ac-
cording to which IPF-AE patients treated with high dose
steroids didn’t survive and secondarily to it our firm
position that such a therapeutic approach would not be
appropriate to treat our IPF-AE patients. Of course we
are very conscious of the fact that the responsibility of
such a scientific opinion that contradicts the official
guidelines, although the latter are based on poor evi-
dence, cannot be easily shouldered and that it should be
incontestably proved by a prospective properly designed
trial examining the role of steroids in the AE-IPF. It is
common sense that a single academic center like ours
could never support by itself such a trial but needs the
scientific, technical and financial support of the inter-
national scientific community and of official medical in-
stitutions that could conduct a multi-center trial
designed and empowered to provide definitive answers
to this already long lasting and crucial for IPF patients
debate. We are convinced that our proposal reflects not
only our view but also the evolving view of other experts
that treat IPF-AE patients worldwide [21, 31, 32].
Conclusions
In conclusion by applying the critically ill patient proto-
col on the management of IPF patients developing acute
exacerbation we have shown that half of our patients
survived. Furthermore, we found that the history of im-
munosuppression before IPF-AE adversely influences
survival. Avoiding steroids in IPF patients may favor the
natural history of the disease even at the moment of its
most devastating event.
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